COSTS OF HYSTEROSCOPIC STERILIZATION VERSUS LAPAROSCOPIC BILATERAL TUBAL LIGATION STERILIZATION AMONG COMMERCIALLY-INSURED WOMEN IN THE UNITED STATES
Author(s)
Carney P1, Yao J2, Lin J3, Law A4
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 3Novosys Health, Green Brook, NJ, USA, 4Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA
OBJECTIVES: To evaluate costs of initial procedures and during a 6-month follow-up period of women who had hysteroscopic sterilization (HS) vs. laparoscopic bilateral tubal ligation. (LBTL) METHODS: Women (18-49 years) continuously insured with claims for HS and LBTL procedures without a concomitant procedure on the same day were identified from the MarketScan Commercial claims database (1/1/2010-12/31/2012). Women were placed into cohorts based on sterilization procedure received. Demographics, characteristics, procedure setting, initial procedure costs, and 6-month procedural-related costs were compared. Procedure-related costs included diagnoses that could be related to a sterilization procedure (eg pelvic pain, wound infection, allergic reaction), selected from a list of all diagnoses that occurred during the follow-up period. Multivariable regression analyses were used to examine the impact of HS vs. LBTL on initial procedure costs and 6-month procedural-related costs while controlling for key patient characteristics. RESULTS: Among the study population, 12,031 had HS (mean age: 37.0 years) and 7,286 had LBTL (mean age: 35.8 years). The majority (80.9%) of women who had HS received the procedure in a physician's office. Fewer women who had HS vs. LBTL received the procedure in an inpatient setting (0.5% vs. 2.1%), a hospital outpatient setting (13.4% vs. 71.9%), and an ambulatory surgical center setting (5.0% vs. 23.8%). Mean total cost for the initial procedure was lower for HS ($3,964) than for LBTL ($5,163, p<0.001). During the 6-month follow-up period sterilization procedure-related costs were lower for women who had HS vs. LBTL ($4,971 vs. $5,407, p<0.001). After controlling for key patient characteristics, multivariable regression results confirmed that initial procedure costs (-$1,215) and 6-month sterilization procedural-related costs (-$456) were less for women who had HS vs. LBTL. CONCLUSIONS: Among commercially-insured women, HS vs. LBTL is associated with lower costs for the initial procedure and lower procedure-related costs 6 months after the sterilization procedure.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PIH20
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Reproductive and Sexual Health